Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study
In our study, RTX was safe and effective in patients with IIM who had an inadequate response or severe disease at admission. Furthermore, the presence of MSAs may predict a favorable response to RTX treatment in patients with IIM.
Authors
- Nevzat KOCA (ORCID: https://orcid.org/0000-0002-0942-0947)
- Murat Bektaş (ORCID: https://orcid.org/0000-0002-1788-3837)
- Emin Oğuz (ORCID: https://orcid.org/0000-0001-8165-7650)
Institutions
- Bahçeşehir University (TR)
- Education Training And Research (US)
- Liv Hospital (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1093/mr/roaf097
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00